Free shipping on all orders over $ 500

 About 6 results found for searched term "55-06-1" (0.058 seconds)

Cat.No.  Name Target
M2815 Liothyronine Sodium Others
T3 Sodium salt; Sodium L-3,3',5-triiodothyronine; Liothyronine sodium
Liothyronine Sodium is the most potent form of thyroid hormone acting on the body to increase the basal metabolic rate, affect protein synthesis.
M17826 Sericic acid Triterpenoids
Sericic acid
M19867 Gatifloxacin hydrochloride Topoisomerase
AM-1155 hydrochloride; CG5501 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride
Gatifloxacin (AM-1155, CG5501, BMS-206584, PD135432) hydrochloride is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases with IC50 of 13.8 μg/ml and 0.109 μg/ml for S. aureus topoisomerase IV and E. coli DNA gyrase, respectively.
M20392 Bimatoprost Prostaglandin Receptor
Bimatoprost is a synthetic prostaglandin analog as well as a prostaglandin F (FP) receptor agonist (FPA) with IOP-lowering activity for studies related to glaucoma and IOP.
M28883 Gatifloxacin sesquihydrate Antibiotic
AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml).
M29902 Gatifloxacin mesylate Antibiotic
AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml).



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.